Table 1.

Baseline characteristics of the study participants according to achieved mean arterial pressure reduction: <20, 20 to <40, and ≥40 mm Hg

VariablesMean Arterial Pressure Reduction
<20 mm Hg, n=113820 to <40 mm Hg, n=1857≥40 mm Hg, n=309
Age, yr67±967±963±9
Cardiovascular disease, %191821
 Clinical161418
 Subclinical555
Women, %333437
Black race, %353140
Baseline BP, mm Hg
 Systolic128±12143±12163±14.8
 Diastolic72±1081±994±11
 Mean91±8102±8117±10
No. of antihypertensive agents1.8±1.01.7±1.01.6±1.1
Body mass index, kg/m230.0±5.730.1±5.730.4±6.6
Serum creatinine, mg/dl0.94±0.170.92±0.170.93±0.19
eGFR, ml/min per 1.73 m281±1581±1683±17
Urinary albumin to creatinine, mg/g7.6 (5.1–14.8)8.9 (5.6–17.6)12.5 (7.7–27.0)
Fasting total cholesterol, mg/dl188±42192±40204±47
Fasting HDL cholesterol, mg/dl52±1353±1455±16
Fasting total triglycerides, mg/dl103 (74–140)107 (76–150)110 (77–168)
Fasting plasma glucose, mg/dl99±1499±1399±17
Statin use, %414131
Aspirin use, %515044
Smoking status, %
 Never smoked424443
 Current smoker161425
 Former smoker424233
  • Baseline characteristics of 3304 Systolic Blood Pressure Intervention Trial participants without CKD at baseline assigned to intensive BP treatment according to achieved mean arterial pressure reduction. Values are percentages for categorical covariates, means±SD for continuous covariates, or medians (interquartile ranges) where appropriate.